Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock fell -1.36% on Thursday to $11.59 against a previous-day closing price of $11.75. With 1.62 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.94 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.75 whereas the lowest price it dropped to was $11.37. The 52-week range on CPRX shows that it touched its highest point at $22.11 and its lowest point at $6.15 during that stretch. It currently has a 1-year price target of $21.40. Beta for the stock currently stands at 1.12.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CPRX was down-trending over the past week, with a drop of -5.00%, but this was down by -27.65% over a month. Three-month performance dropped to -24.05% while six-month performance fell -33.81%. The stock gained 68.70% in the past year, while it has lost -37.69% so far this year. A look at the trailing 12-month EPS for CPRX yields 0.88 with Next year EPS estimates of 1.45. For the next quarter, that number is 0.28. This implies an EPS growth rate of 103.70% for this year and 25.00% for next year.
Float and Shares Shorts:
At present, 105.56 million CPRX shares are outstanding with a float of 97.66 million shares on hand for trading. On Apr 27, 2023, short shares totaled 11.19 million, which was 10.56% higher than short shares on Mar 30, 2023. In addition to Mr. Patrick J. McEnany as the firm’s Co-Founder, Chairman, Pres & CEO, Ms. Alicia Grande C.M.A., CPA, CMA, CPA serves as its Chief Accounting Officer, VP, Treasurer & CFO.
Institutional Ownership:
Through their ownership of 82.72% of CPRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.40% of CPRX, in contrast to 40.89% held by mutual funds. Shares owned by individuals account for 14.44%. As the largest shareholder in CPRX with 13.28% of the stake, BlackRock Fund Advisors holds 14,074,282 shares worth 14,074,282. A second-largest stockholder of CPRX, Deerfield Management Co. LP, holds 10,355,099 shares, controlling over 9.77% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in CPRX, holding 7,542,718 shares or 7.12% stake. With a 6.56% stake in CPRX, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 6,951,574 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.78% of CPRX stock, is the second-largest Mutual Fund holder. It holds 4,002,502 shares valued at 63.72 million. Vanguard Total Stock Market ETF holds 2.90% of the stake in CPRX, owning 3,068,116 shares worth 48.84 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, CPRX reported revenue of $53.11M and operating income of $28.57M. The EBITDA in the recently reported quarter was $28.61M and diluted EPS was $0.20.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CPRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CPRX analysts setting a high price target of $25.00 and a low target of $15.00, the average target price over the next 12 months is $21.40. Based on these targets, CPRX could surge 115.7% to reach the target high and rise by 29.42% to reach the target low. Reaching the average price target will result in a growth of 84.64% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded CPRX stock several times over the past three months with 8 Buys and 13 Sells. In these transactions, 270,000 shares were bought while 270,000 shares were sold. The number of buy transactions has increased to 62 while that of sell transactions has risen to 70 over the past year. The total number of shares bought during that period was 2,589,810 while 3,837,162 shares were sold.
